Related Experiment Video

Updated: Jun 2, 2026

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
10:19

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

Compounding artefacts with uncertainty, and an amyloid cascade hypothesis that is 'too big to fail'

Rudy J Castellani1, Mark A Smith

  • 1Department of Pathology, University of Maryland, Baltimore, MD, USA. rcastellani@som.umaryland.edu

The Journal of Pathology
|May 11, 2011
PubMed

Insights

Despite numerous failed clinical trials, anti-amyloid therapies for Alzheimer's disease persist. The amyloid cascade hypothesis, central to Alzheimer's research, faces significant challenges and may be too entrenched to abandon.

Area of Science:

  • Neuroscience
  • Neuropathology
  • Pharmacology

Background:

  • The amyloid cascade hypothesis has long dominated Alzheimer's disease (AD) research and therapeutic development.
  • Numerous clinical trials targeting amyloid-beta (Aβ) have failed to demonstrate efficacy, yet research continues.
  • The hypothesis has evolved, making it difficult to definitively prove or disprove.

Purpose of the Study:

  • To critically evaluate the continued reliance on the amyloid cascade hypothesis in Alzheimer's disease research.
  • To highlight inconsistencies and overlooked factors that challenge the hypothesis's validity.
  • To question the persistence of Aβ-centric approaches despite accumulating negative trial data.

Main Methods:

  • Review and critical analysis of existing literature on Alzheimer's disease pathogenesis and Aβ-targeting therapies.
  • Examination of discrepancies between Aβ pathology and clinical presentation in AD.
  • Assessment of the scientific basis for current therapeutic strategies.

Main Results:

  • Poor correlation exists between amyloid-beta plaque burden and cognitive decline in Alzheimer's disease.
  • Significant differences between familial and sporadic AD forms are not adequately explained by the hypothesis.
  • Pathological evidence suggests amyloid and related lesions may be secondary rather than primary drivers of AD.
  • Soluble Aβ species are difficult to reproduce reliably in laboratory settings.
  • Synaptic assessments have limited relevance to pathological interpretations.

Conclusions:

  • The amyloid cascade hypothesis, despite its dominance, is not well-supported by current evidence and faces significant challenges.
  • Overlooked factors and inconsistencies warrant a re-evaluation of AD's underlying mechanisms.
  • The neuroscience community's persistent adherence to the hypothesis, irrespective of outcome data, raises concerns about scientific inertia.

More Related Videos

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease06:52

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease

Published on: July 6, 2019

Biochemical Purification and Proteomic Characterization of Amyloid Fibril Cores from the Brain09:00

Biochemical Purification and Proteomic Characterization of Amyloid Fibril Cores from the Brain

Published on: April 28, 2022

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...